SkyePharma makes senior appointments
UK-based SkyePharma has appointed a new senior management team comprising Frank Condella as chief executive and Dr Ken Cunningham in the newly created post of chief operating officer.
UK-based SkyePharma has appointed a new senior management team comprising Frank Condella as chief executive and Dr Ken Cunningham in the newly created post of chief operating officer.
This new role will focus on ensuring the effective development of SkyePharma's key products such as Flutiform.
Condella was president of the European operations of IVAX prior to its acquisition by Teva in 2005. He was closely involved with IVAX's respiratory franchise, including managing the acquisition and integration of 3M's branded respiratory business.
Cunningham was chief executive of the privately owned UK biotechnology company Arakis, recently acquired by the Japanese company Sosei for US$200m. He has extensive experience in the development of respiratory products.
The appointment of Dr Jerry Karabelas as non-executive chairman was announced earlier this month. Karabelas had senior roles at two major league pharmaceutical companies as chief executive of Novartis Pharma and president of North American operations for SmithKline Beecham.